Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HCC70 | Pictilisib | 1 | 72 | 3.2 | 1105.0 | 3399.0 | 1279.8 | 0.505 | -0.099 | 0.325 | 1.409 | HCC70 GDC0941 0 1 72 |
Hs 578T | CAL-101 | 3 | 72 | 3.2 | 3370.5 | 4189.5 | 571.3 | 0.505 | 0.854 | 0.805 | 2.874 | Hs578T CAL101 3 |
BT-549 | Alpelisib | 1 | 72 | 3.2 | 4299.5 | 5499.0 | 1554.9 | 0.505 | 0.747 | 0.782 | 1.822 | BT549 BYL719 0 1 72 |
BT-549 | MK2206 | 1 | 72 | 3.2 | 6334.0 | 5457.0 | 1554.9 | 0.505 | 1.170 | 1.160 | 1.811 | BT549 MK2206 0 1 72 |
HCC70 | Sirolimus | 3 | 72 | 3.2 | 2097.5 | 3026.3 | 517.3 | 0.505 | 0.732 | 0.693 | 2.548 | HCC70 Rapamycin 0 3 72 |
HCC1806 | PI103 | 1 | 72 | 3.2 | 9624.3 | 11113.3 | 1742.8 | 0.505 | 0.895 | 0.866 | 2.673 | HCC1806 PI103 0 1 72 |
HCC70 | Pictilisib | 3 | 72 | 3.2 | 992.8 | 2827.0 | 517.3 | 0.505 | 0.305 | 0.351 | 2.450 | HCC70 GDC0941 0 3 72 |
BT-20 | XL147 | 1 | 72 | 3.2 | 5132.5 | 6311.0 | 1443.3 | 0.505 | 0.815 | 0.813 | 2.128 | BT20 XL147 0 1 |
Hs 578T | Trametinib | 1 | 72 | 3.2 | 857.0 | 3601.0 | 873.1 | 0.505 | -0.009 | 0.238 | 2.044 | Hs578T Trametinib 1 |
HCC70 | Torin2 | 2 | 72 | 3.2 | 187.8 | 2562.3 | 722.8 | 0.505 | -0.522 | 0.073 | 1.826 | HCC70 Torin2 0 2 72 |
HCC38 | PIK-93 | 2 | 72 | 3.2 | 2011.0 | 2975.5 | 690.5 | 0.505 | 0.661 | 0.676 | 2.107 | HCC38 PIK93 0 2 72 |
HCC1806 | MK2206 | 1 | 72 | 3.2 | 8994.8 | 11692.5 | 1742.8 | 0.505 | 0.818 | 0.769 | 2.746 | HCC1806 MK2206 0 1 72 |
HCC38 | Sirolimus | 2 | 72 | 3.2 | 1829.3 | 2971.8 | 690.5 | 0.505 | 0.588 | 0.616 | 2.105 | HCC38 Rapamycin 0 2 72 |
HCC1806 | KIN001-244 | 1 | 72 | 3.2 | 11439.0 | 11660.3 | 1742.8 | 0.505 | 0.986 | 0.981 | 2.742 | HCC1806 KIN001-244 0 1 72 |
HCC70 | Buparlisib | 3 | 72 | 3.2 | 341.8 | 2804.3 | 517.3 | 0.505 | -0.156 | 0.122 | 2.439 | HCC70 BKM120 0 3 72 |
BT-20 | ZSTK474 | 1 | 72 | 3.2 | 1504.8 | 5537.8 | 1443.3 | 0.505 | 0.022 | 0.272 | 1.940 | BT20 ZSTK474 0 1 |
HCC38 | TGX221 | 2 | 72 | 3.2 | 2709.3 | 2993.0 | 690.5 | 0.505 | 0.908 | 0.905 | 2.116 | HCC38 TGX221 0 2 72 |
BT-549 | KIN001-244 | 1 | 72 | 3.2 | 4812.3 | 5422.3 | 1554.9 | 0.505 | 0.872 | 0.888 | 1.802 | BT549 KIN001-244 0 1 72 |
HCC38 | Trametinib | 3 | 72 | 3.2 | 1419.3 | 3307.5 | 1180.5 | 0.505 | 0.132 | 0.429 | 1.486 | HCC38 Trametinib 0 3 72 |
BT-549 | AS605240 | 1 | 72 | 3.2 | 4915.0 | 5429.5 | 1554.9 | 0.505 | 0.893 | 0.905 | 1.804 | BT549 AS605240 0 1 72 |
HCC38 | MK2206 | 3 | 72 | 3.2 | 2602.0 | 3214.0 | 1180.5 | 0.505 | 0.728 | 0.810 | 1.445 | HCC38 MK2206 0 3 72 |
HCC1806 | Omipalisib | 1 | 72 | 3.2 | 569.3 | 11840.0 | 1742.8 | 0.505 | -0.333 | 0.048 | 2.764 | HCC1806 GSK458 0 1 72 |
HCC70 | Everolimus | 1 | 72 | 3.2 | 2369.0 | 3299.0 | 1279.8 | 0.505 | 0.569 | 0.718 | 1.366 | HCC70 Everolimus 0 1 72 |
BT-20 | AS605240 | 2 | 72 | 3.2 | 2797.5 | 3661.0 | 1018.6 | 0.505 | 0.729 | 0.764 | 1.846 | BT20 AS605240 0 2 |
BT-549 | Omipalisib | 1 | 72 | 3.2 | 1043.3 | 5372.5 | 1554.9 | 0.505 | -0.200 | 0.194 | 1.789 | BT549 GSK458 0 1 72 |